Christopher Darr, Thomas Hilser, Claudia Kesch, Aykhan Isgandarov, Henning Reis, Milan Wahl, Isabel Kasper-Virchow, Boris A Hadaschik, Viktor Grünwald
Immune-checkpoint-inhibitor (ICI) therapy has been one of the major advances in the treatment of a variety of advanced or metastatic tumors in recent years. Therefore, ICI-therapy is already approved in first-line therapy for multiple tumors, either as monotherapy or as combination therapy. However, there are relevant differences in approval among different tumor entities, especially with respect to PD-L1 testing. Different response to ICI-therapy has been observed in the pivotal trials, so PD-L1 diagnostic testing is used for patient selection...
May 1, 2023: Advances in Anatomic Pathology